Arkolith/Insider Trading/OTLC/Form 4

Trieu Vuong

CHAIRMAN AND CEO, Director, 10% OwnerOncotelic Therapeutics, Inc. (OTLC) · full profile →Form 4 · filed Nov 25, 2022
Net Buying
Open-Market Buys
$6K
Open-Market Sells
$0
Net Open-Market Flow
$6K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 22, 2022Buy(P)70K$0.08$6K90.4M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-033681) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML